

## **Pharmaceutical Packaging Agreement with Aspen Pharmacare**

### **Highlights**

- AusCann has appointed TGA licensed Aspen Pharmacare Australia to provide packaging services for its medicinal cannabis pharmaceutical products.
- Appointment of Aspen Pharmacare is consistent with AusCann's careful management of its supply chain and cost base:
  - de-risks supply chain through partnering with leading service providers, and
  - follows a detailed supply chain fiscal analysis to ensure the most economically prudent packaging solution.
- AusCann's proprietary hard shell capsules will be packaged by Aspen in consumer ready packs at its Australian facilities.

**25 November 2019** – Leading medical cannabis company **AusCann Group Holdings Limited** (ASX: AC8) (AusCann or 'the Company') is pleased to announce it has appointed TGA licensed Aspen Pharmacare Australia Pty Ltd ('Aspen') to provide packaging for its medicinal cannabis pharmaceutical products. The appointment of Aspen derives from AusCann's careful management of its supply chain and cost base, and aims to de-risk the supply chain in the most cost effective manner, ensure quality compliance, and follows similar partnerships with cultivation & extraction, manufacturing, and controlled distribution service providers.

The agreement with Aspen is for an initial three year period that can be extended and will include GMP packaging services for AusCann's proprietary solid hard shell capsules. These will be manufactured under contract by AusCann's manufacturing partner, PCI Pharma, and will be packaged by Aspen in consumer ready packs at its Australian facility. This agreement is the result of a detailed financial analysis that indicated a considerable cost benefit for packaging outsourcing with Aspen.

Aspen Pharmacare Australia is a subsidiary of Aspen Pharmacare Holdings Limited, the largest listed pharmaceutical company in South Africa. It has an established business presence in over 56 countries including Australia, and is a global supplier of branded and generic pharmaceutical products to more than 150 countries. The company has 25 manufacturing facilities on 17 sites around its global operations, and is licensed by the United States Food and Drug Administration, the Australian Therapeutic Goods Administration (TGA) and the European Directorate for the Quality of Medicines.

**AusCann CEO, Mr Ido Kanyon** said the appointment of Aspen is consistent with AusCann's need for pharmaceutical grade GMP packaging and quality as well as AusCann's requirement that all steps taken in the development of the commercial supply chain be done in a cost-efficient manner.

"AusCann has established capabilities and partnerships with leading service providers across the full medicinal cannabis supply chain. This allows us to focus our capital on where we can deliver the best sustainable value for our shareholders – on market ready cannabinoid-based

pharmaceutical product development, generating clinical evidence for these superior products and building medical acceptance from Doctors.

"AusCann is on track in getting its first capsules to market. These are expected to be released for clinical trials towards the end of 2019. The manufacturing of the cannabinoid hard shell capsules will be primarily manufactured under contract by our manufacturing partner PCI Pharma, with packaging by Aspen Pharmacare. The contract manufacturing and packaging capabilities we have in place with Aspen Pharmacare and with PCI Pharma enable us to be highly cost-effective and agile."

## ENDS

### For more information, please contact:

#### For Investment Enquiries

Quentin Megson  
Chief Operating and Financial Officer  
info@auscann.com.au  
+61 8 9561 8834

#### For Media Enquiries

Elodie Castagna  
FTI Consulting  
elodie.castagna@fticonsulting.com  
+61 8 9321 8533

## ABOUT AUSCANN

**AusCann Group Holdings Limited** (ASX:AC8) is an Australian-based pharmaceutical company focused on the development, production, and distribution of cannabinoid-based medicines within Australia and internationally. AusCann transforms the way Medicinal Cannabis is dispensed today by making standardised dose-controlled cannabinoid-based pharmaceutical products and clinical evidence accessible to patients, physicians and healthcare providers. AusCann enables physicians to treat their patients with a reliable, stable and standardised cannabinoid-based pharmaceutical product, monitor treatment results and adjust treatment algorithms using a portfolio of products and formulations.

## ABOUT ASPEN PHARMACARE

Aspen Pharmacare is a leading specialty and branded multinational pharmaceutical company employing more than 10,000 people in 52 countries. Aspen has a 20-year history and is well positioned in both emerging and developed markets and markets and distributes products renowned for quality, efficacy and affordability.

Core therapeutic categories include Regional Brands, Anaesthetics, Thrombosis and High Potency & Cytotoxics.

Aspen has world class facilities with international approvals from global regulatory agencies. The Group manufactures more than 24 billion tablets annually from 25 manufacturing facilities on 17 sites, and provides products to over 150 countries.

Aspen's manufacturing capability covers a wide range of product types including injectables, oral solid dose, liquids, semi-solids, steriles, biologicals and active pharmaceutical ingredients.